Naltrexone Prodrugs for Transdermal Delivery
Naltrexone Prodrugs for Transdermal Delivery
批准号:
7597157
负责人:
Audra L. Stinchcomb
金额:
$31.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-04-01 至 2011-03-31
关键词:
Adverse effectsAlcohol abuseAlcohol dependenceAlcoholismCaviaDataDatabasesDiffusionDosage FormsDoseDrug Delivery SystemsDrug KineticsGoalsHeatingHumanHydrogen BondingIn VitroKnowledgeLeadMeasuresMolecularMolecular WeightNaltrexoneNarcotic AntagonistsOpiate AddictionOpioidOralPenetrationPermeabilityPharmaceutical PreparationsPharmacotherapyPlasmaPopulationProdrugsPropertyRecoveryReportingResearchRestSeriesSkinSolubilitySolventsStructureSystemTabletsTherapeuticUnited Statesalcohol cravingclinical applicationcostcravingdesignimprovedin vivoin vivo Modellipophilicitymeltingnaltrexolproblem drinkerresearch and developmenttool
中文摘要
描述(由申请人提供):酒精中毒和阿片类药物成瘾导致美国和世界其他地区人民的主要健康相关问题和社会成本。因此,研究和开发用于药物和酒精滥用的改进的药物治疗是非常重要的。纳洛酮是一种阿片类拮抗剂,目前以口服片剂形式使用,以帮助维持阿片类成瘾者处于无毒状态。最近,纳洛酮已被指示为治疗酒精依赖的辅助药物,并据报道可减少某些酒精中毒人群的酒精渴望。纳洛酮的透皮递送对于阿片类成瘾者和酗酒者是理想的,以帮助减少与口服治疗相关的副作用并提高依从性。纳洛酮本身不具有允许治疗剂量的药物穿过人体皮肤屏障的基本物理化学性质。我们计划继续设计和合成比纳洛酮更具有皮肤渗透性的前药,以制造治疗上成功的药物递送系统。我们假设纳曲酮的前药和前药与微针治疗的组合将提高纳曲酮的透皮递送速率,并且这些前药将成为研究透皮通量的定量结构-渗透性关系(QSPR)和与微针增强组合的通量优化的极好的研究工具。这些前药/微针应改善纳洛酮通过皮肤的递送速率,因为优化的物理化学性质用于更快的扩散。该项目的具体目标包括:(1)合成了一系列纳曲酮和纳曲醇,(活性代谢物)前药,其设计用于阐明在使用和不使用微针的情况下用于经皮通量优化的基本QSPR,(2)表征药物的物理化学参数,包括分子量、分子体积、亲脂性、氢键键合势、熔点、熔化热,和在选择的溶剂中的溶解度,(3)在体外使用和不使用微针的情况下测量药物通过人皮肤的渗透和同时的生物转化,和(4)在体内使用和不使用微针的情况下表征药物在豚鼠中的药代动力学。我们的体外数据与体内模型的相关性将有助于建立一个可靠的QSPR数据库,用于透皮前药与微针的使用,以及帮助确定最有前途的前药/微针系统,最终人类使用。
英文摘要
DESCRIPTION (provided by applicant): Alcoholism and opiate addiction lead to major health-related problems and societal costs for people in the United States and the rest of the world as well. Therefore, research and development for improved pharmacologic treatments for drug and alcohol abuse are very important. Naltrexone, an opioid antagonist, is currently used in oral tablet form to help maintain opioid addicts in a drug-free state. Most recently, naltrexone has been indicated as an adjunct in the treatment of alcohol dependence, as well as reported to reduce alcohol craving in certain alcoholic populations. Transdermal delivery of naltrexone is desirable for opioid addicts and alcoholics in order to help reduce side effects associated with oral therapy and improve compliance. Naltrexone itself does not have the essential physicochemical properties that would allow a therapeutic dose of the drug to cross the human skin barrier. We plan to continue designing and synthesizing prodrugs, which are more skin permeable than naltrexone, in order to make a therapeutically successful drug delivery system. We hypothesize that prodrugs of naltrexone and prodrugs in combination with microneedle treatment will improve the transdermal delivery rate of naltrexone, and that these prodrugs will make excellent research tools for investigating quantitative structure-permeability relationships (QSPR) for transdermal flux and optimization of flux in combination with microneedle enhancement. These prodrugs/microneedles should improve naltrexone delivery rates across the skin because of optimized physicochemical properties for faster diffusion. The specific aims of this project include: (1) to synthesize a series of naltrexone and naltrexol (active metabolite) prodrugs designed to elucidate fundamental QSPRs for transdermal flux optimization with and without microneedle use, (2) to characterize the physicochemical parameters of the drugs, including molecular weight, molecular volume, lipophilicity, hydrogen-bonding potentials, melting points, heats of fusion, and solubilities in select solvents, (3) to measure the drugs' penetration and concurrent bioconversion through human skin in vitro with and without microneedle use, and (4) to characterize the pharmacokinetics of the drugs in guinea pigs in vivo with and without microneedle use. Correlation of our in vitro data with the in vivo model will aid in the creation of a reliable QSPR database for transdermal prodrugs with and without microneedle use, as well as help to identify the most promising prodrug/microneedle system for eventual human use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heat Effect on Generic Transdermal Drug Delivery Systems
-
批准号:9340991
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2013
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
-
批准号:8253142
-
项目类别:
-
资助金额:$53.78万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppressi
-
批准号:8508902
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Naltrexone for Opiate Addiction and Alcoholism
-
批准号:8519709
-
项目类别:
-
资助金额:$69.6万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Microneedle-enhanced codrug delivery for smoking cessation and appetite suppressi
-
批准号:8303925
-
项目类别:
-
资助金额:$20.36万
-
财政年份:2012
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Cannabidiol Prodrug Delivery
-
批准号:8199298
-
项目类别:
-
资助金额:$16.05万
-
财政年份:2011
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal delivery of 2-Arachidonoyl glycerol (2-AG) for the treatment of arthr
-
批准号:8279206
-
项目类别:
-
资助金额:$7.68万
-
财政年份:2011
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal delivery of 2-Arachidonoyl glycerol (2-AG) for the treatment of arthr
-
批准号:8516633
-
项目类别:
-
资助金额:$5.91万
-
财政年份:2011
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Cannabinoid Prodrug Treatment for Cannabis Withdrawal and Dependence
-
批准号:7943910
-
项目类别:
-
资助金额:$193.25万
-
财政年份:2009
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Delivery of Buprenorphine Prodrugs
-
批准号:7611813
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2009
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Cannabinoid Prodrug Treatment for Cannabis Withdrawal and Dependence
-
批准号:7861337
-
项目类别:
-
资助金额:$208.07万
-
财政年份:2009
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:7024607
-
项目类别:
-
资助金额:$35.96万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:6710705
-
项目类别:
-
资助金额:$36.8万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:6865678
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Transdermal Codrugs for Treatment of Alcoholism
-
批准号:6555545
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2003
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6623667
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6469406
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6711688
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:7798621
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
Naltrexone Prodrugs for Transdermal Delivery
-
批准号:6937298
-
项目类别:
-
资助金额:$6.15万
-
财政年份:2002
-
负责人:Audra L. Stinchcomb
-
依托单位:
海外基金